Evergraf 0.5mg tablet - Everolimus | Apple Pharmaceuticals

Description

Evergraf 0.5mg consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.
Evergraf 0.5mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

Primarily Evergraf 0.5mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism Of Action

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage

Evergraf 0.5mg tablets should be given with or without food.
The dosage regimen of Evergraf 0.5mg;
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Precautions

Lymphomas:
The developed hazard of skin cancers, the patient may protect from UV light

Serious infections :
Patients getting Evergraf 0.5mg have a severe risk of achieving various infections related to bacteria, virus, and fungi.

Hepatic artery thrombosis :
Evergraf 0.5mg therapy should not be recommended in liver transplant patients,

Nephrotoxicity :
While using Evergraf 0.5mg in renal impaired patients Renal function should be monitored frequently; drug use with caution.

Drug Interaction

Evergraf 0.5mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Evergraf 0.5mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Evergraf 0.5mg with cyclosporine will increase the AUC level of Everolimus frequently.
Combination ketoconazole with Evergraf 0.5mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy

Pregnancy category of Everolimus C
In patients, Evergraf 0.5mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

Lactation

Breastfeeding should not be suggested

Storage

Evergraf 0.5mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with a medical practitioner and follow the instructions given by them.
Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evergraf-0.5mg.php

Evergraf 0.25mg tablet:Everolimus Price | Apple pharmaceuticals

Description

Evergraf 0.25mg consists of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down.
Evergraf 0.25mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

Primarily Evergraf 0.25mg tablets indicated for the treatment
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism Of Action

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis

Dosage

Evergraf 0.25mg tablets should be given with or without food.
The dosage regimen of Evergraf 0.25mg;
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evergraf as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evergraf as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Precautions

Lymphomas:
The developed hazard of skin cancers, the patient may protect from UV light

Serious infections:
Patients getting Evergraf 0.25mg have a severe risk of achieving various infections related to bacteria, virus, and fungi.

Hepatic artery thrombosis:
Evergraf 0.25mg therapy should not be recommended in liver transplant patients,

Nephrotoxicity:
While using Evergraf 0.25mg in renal impaired patients Renal function should be monitored frequently; drug use with caution.

Drug Interaction

Evergraf 0.25mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Evergraf 0.25mg with strong CYP3A4 inducers will be increasing the disclosure of Everolimus.
Combination of Evergraf 0.25mg with cyclosporine will be increasing the AUC level of Everolimus frequently.
Combination ketoconazole with Evergraf 0.25mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy

Pregnancy category of Everolimus C
In patients, Evergraf 0.25mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

Lactation

Breastfeeding should not be suggested

Storage

Evergraf 0.25mg tablet store at 25°C.
Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them.
Thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evergraf-0.25mg.php

Evertor 10mg Tablet | Apple Pharmaceuticals

Description

Evertor consist of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and the process is slowed down. Evertor tablets is not a curable medication, which helps to slow their spreading into the body.

Indication of Evertor

Primarily Evertor tablets indicated for the treatment :
kidney carcinoma
Breast carcinoma
Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, Finally causes cell growth arrest and apoptosis

Dosage regimen of Evertor

In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
 The prescribed dosage is 10mg should be taken as a single dose.
 In Brain or intracranial cancer:
 The prescribed dosage of Evertor as a single dose. is 4.5mg/m2 given orally
 In pediatric:
 The pediatric dosage of Evertor as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

Side Effects

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes.

Drug-Drug interaction

Evertor interaction with strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Interaction of Evertor with strong CYP3A4 inducers will increase the disclosure of Everolimus. Combination of Evertor with cyclosporine will increase the AUC level of Everolimus frequently. Combination ketoconazole with Evertor tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus.

Pregnancy and lactation

Pregnancy category of Everolimus In patients Evertor is used only after knowing the benefits to the mother exceed the risk to the fetus. Breastfeeding should not be suggested

Storage and handling

Evertor tablet store at 25°C Store the medicine away from moisture, heat, and light

Missed Dose

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evertor-10mg.php

Evertor 5mg tablet - Everolimus | Apple Pharmaceuticals

Description

Evertor 5mg consists of an active ingredient known as Everolimus which is intruded with the growth of cancer cell and process is slowed down.
Evertor 5mg tablets is not a curable medication, which helps to slow their spreading into the body.

Indication

 Primarily Evertor 5mg tablets indicated for the treatment :
* kidney carcinoma
* Breast carcinoma
* Brain carcinoma
Everolimus is also indicated in various advanced stage cancer in stomach, intestines or pancreas.

Mechanism

Everolimus is an inhibitor of mTOR, joins at high compatibility to FK506 binding protein 12, via producing drug complex that inhibits the production of mTOR.
This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, Finally causes cell growth arrest and apoptosis

Dosage and administration

Evertor 5mg tablets should be given with or without food.
Dosage regimen of Evertor 5mg;
In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer:
The prescribed dosage is 10mg should be taken as a single dose.
In Brain or intracranial cancer:
The prescribed dosage of Evertor as a single dose. is 4.5mg/m2 given orally
In pediatric:
The pediatric dosage of Evertor as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

side effects

Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes.

Drug interaction

Evertor 5mg interaction with strong inhibitor of CYP3A4, or P-g p, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus.
Interaction of Evertor 5mg with strong CYP3A4 inducers will increase the disclosure of Everolimus.
Combination of Evertor 5mg with cyclosporine will be increasing the AUC level of Everolimus frequently.
Combination ketoconazole with Evertor 5mg tablet or other CYP3A4 inhibitors will increase the plasma concentration and AUC of Everolimus. Concomitant use of Evertor 5mg with verapamil leads to increasing the plasma concentration of Everolimus.

Storage

Evertor 5mg tablet store at 25°C
Store the medicine away from moisture, heat, and light

Missed Dose

The over dosage of Everolimus is limited If overdosage occurs patient must be provided with supportive measures. And monitor evidence of toxicity in Everolimus overdosage

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/evertor-5mg.php

Revolade 25mg tablet online | Apple pharmaceuticals

Description

Eltrombopag is an oral tablet which is available as the brand-name drug Revolade 25mg. The drug is not available as a generic drug.
Revolade 25mg is a prescription drug which is used under the guidance of the doctor.
Revolade 25mg drug may be used as part of combination therapy. Thereby drug may need to take it with other medications.

Indication

Revolade 25mg is mainly indicated for the treatment of patients having :
• Reduced platelet levels due to chronic immune thrombocytopenia
• Reduced platelet counts due to chronic hepatitis C virus infection
• Severe Aplastic Anemia :
• First line treatment of severe Aplastic Anemia
• Treatment of refractory severe Aplastic Anemia.

Mechanism Of Action

Revolade is part of a class of drugs called thrombopoietin (TPO) receptor agonists. Classification of drugs is an association of medications which work in a similar way. These drugs are often used to treat similar conditions. Revolade works by raise cells in bone marrow and leads these cells to make various platelets. This effect reduces the risk of bleeding.

Dosage and administration

Chronic Immune Thrombocytopenia:
Indicated only in patients with chronic immune thrombocytopenia whose clinical condition increases bleeding risk
Initial:
50 mg PO qDay
Adjust dose to achieve and control platelet count (Plt) >50 x 10^9/L to lowers risk of bleeding; not to exceed 75 mg/day
Chronic Hepatitis C-associated Thrombocytopenia
Initial: 
25 mg PO qDay
Dose is Adjust in 25 mg accretion q2weeks PRN to attain target Pelt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
During antiviral therapy, regulate dose to stop dose reductions of peginterferon
Severe Aplastic Anemia

Precautions

The drug causes warning condition, call the doctor while new medication interaction
Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increase the risk of death.
If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.
If the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse.

Drug Interaction

Revolade 25mg interaction with these drugs ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads an increase of side effects. hence the doctor may reduce your dosage of these drugs if required.

Pregnancy

Pregnancy category is C
Use the Revolade 25mg with caution if asset outweighs risks. Animal studies reveal risk and human studies not available or neither animal nor human studies done.

Serious Side Effects

• Urine in dark color
• Yellowing of your skin
• Abdomen swelling
• Confusion
• Chest pain
• Dyspnea
• Cloudy vision
• Sensitivity to light
• Seeing circles around lights
• Swelling of legs.

Missed Dose

In case of a missed dose, patients must consult with a medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

Storage

Store at room temperature 20°C to 25°C.
Discard the left-out medicine if not used within 30 minutes

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/revolade-25mg.php

Opdyta 100mg tablet online | Apple pharmaceuticals

Description

Nivolumab is a generic form of brand name Opdyta 100mg which is a targeted therapy drug presently used to cure from melanoma, non-small cell lung cancer or kidney (renal cell) cancer. Opdyta 100mg belongs to a group of cancer drugs known as monoclonal antibodies.
Opdyta 100mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.

Indication

Opdyta 100mg is indicated for the treatment of patients having conditions like :
• Melanoma which has spread or can’t be removed with surgery
• Non-Small Cell Lung Cancer which has spread or come back after chemotherapy
• Kidney (Renal Cell) Cancer which has come back after chemotherapy.

Mechanism Of Action

Opdyta stops the molecule activity called PD-1, and it is a protein which inhibits T cells from identifying and attacking inflamed tissues and cancer cells. PD-1 can trick the immune system into overlooking melanoma cells as normal cells. Opdyta triggers your immune system’s reacting to melanoma by inhibiting the PD-1 protein on T cells. The drug activates T cells so which they can attack melanoma cells anywhere in your body.

Dosage and administration

Opdyta recommended dosage for unresectable or metastatic melanoma : 
As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity
With ipilimumab. The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment

Precautions

Immune-mediated pneumonitis may appear to the patients; withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis
Immune-mediated colitis resulted; withhold for moderate or serious and permanently stop for life-threatening colitis
Immune-mediated hepatitis seen in clinical trials; check for liver function changes; withhold for limited and permanently stop for serious or life-threatening transaminase or total bilirubin elevation.

Pregnancy

The effects of Opdyta 100mg are expected to be greater during the second and third trimesters of pregnancy. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

Storage

Store at under refrigeration at 2°C to 8°C.

Missed Dose

If you missed a dose take it as soon as possible, if time reach for next dose, then skip the missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking a missed dose within 12hrs of the next dose.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/opdyta-100mg.php

Opdyta 40mg tablet online | Apple pharmaceuticals

Description

Nivolumab is a generic form of brand name Opdyta 40mg which is a targeted therapy drug presently used to cure from melanoma, non-small cell lung cancer or kidney (renal cell) cancer. Opdyta 40mg belongs to a group of cancer drugs known as monoclonal antibodies.
Opdyta 40mg is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.

Indication

Opdyta 40mg is indicated for the treatment of patients having conditions like :
• Melanoma which has spread or can’t be removed with surgery
• Non-Small Cell Lung Cancer which has spread or come back after chemotherapy
• Kidney (Renal Cell) Cancer which has come back after chemotherapy.

Mechanism Of Action

Opdyta stops the molecule activity called PD-1, and it is a protein which inhibits T cells from identifying and attacking inflamed tissues and cancer cells. PD-1 can trick the immune system into overlooking melanoma cells as normal cells. Opdyta triggers your immune system’s reacting to melanoma by inhibiting the PD-1 protein on T cells. The drug activates T cells so which they can attack melanoma cells anywhere in your body.

Dosage and administration

Opdyta recommended dosage for unresectable or metastatic melanoma : 
As single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity
With ipilimumab. The recommended dose of Opdyta is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination dose continue the single agent treatment

Precautions

Immune-mediated pneumonitis may appear to the patients; withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis
Immune-mediated colitis resulted; withhold for moderate or serious and permanently stop for life-threatening colitis
Immune-mediated hepatitis seen in clinical trials; check for liver function changes; withhold for limited and permanently stop for serious or life-threatening transaminase or total bilirubin elevation.

Pregnancy

The effects of Opdyta 40mg are expected to be greater during the second and third trimesters of pregnancy. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

Storage

Store at under refrigeration at 2°C to 8°C.

Missed Dose

If you missed a dose take it as soon as possible, if time reach for next dose, then skip the missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking a missed dose within 12hrs of the next dose.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/opdyta-40mg.php

Nivolumab (Opdyta 40 & 100 mg) Injection online | Apple pharmaceuticals

Description

Nivolumab is a generic form of brand name Nivolumab which is a targeted therapy drug presently used to cure melanoma, non-small cell lung cancer or kidney (renal cell) cancer. Nivolumab belongs to a group of cancer drugs known as monoclonal antibodies.
Nivolumab is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells.

Indication

Nivolumab is indicated for the treatment of patients having conditions like :
• Melanoma which has spread or can’t be removed with surgery
• Non-Small Cell Lung Cancer which has spread or come back after chemotherapy
• Kidney (Renal Cell) Cancer which has come back after chemotherapy.

Mechanism Of Action

Nivolumab stops the molecule activity called PD-1, and it is a protein which inhibits T cells from identifying and attacking inflamed tissues and cancer cells. PD-1 can trick the immune system into overlooking melanoma cells as normal cells. Nivolumab triggers your immune system’s reacting to melanoma by inhibiting the PD-1 protein on T cells. The drug activates T cells so which they can attack melanoma cells anywhere in your body.

Dosage and administration

Nivolumab recommended dosage for unresectable or metastatic melanoma : 
As a single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity
With ipilimumab. The recommended dose of Nivolumab is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination does continue the single agent treatment

Side Effects

Common side effects :
Fatigue, Lymphocytopenia (Low White Blood Cells), Low Sodium, Shortness of breath, Musculoskeletal Pain, Decreased Appetite, Cough.

Precautions

Immune-mediated pneumonitis may appear to the patients; withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis
Immune-mediated colitis resulted; withhold for moderate or serious and permanently stop for life-threatening colitis
Immune-mediated hepatitis seen in clinical trials; check for liver function changes; withhold for limited and permanently stop for serious or life-threatening transaminase or total bilirubin elevation.

Pregnancy

The effects of Nivolumab are expected to be greater during the second and third trimesters of pregnancy. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus.

Lactation

Nivolumab Excretion in human breast milk is not known; advise women to discontinue breastfeeding during treatment

Missed Dose

If you missed a dose take it as soon as possible, if time reach for next dose, then skip the missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking a missed dose within 12hrs of the next dose.

Storage

Store at under refrigeration at 2°C to 8°C.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/nivolumab.php

Eltrombopag tablet online | Apple pharmaceuticals

Description

Eltrombopag is a prescription drug which is used under the guidance of the doctor.
Eltrombopag drug may be used as part of combination therapy. Thereby drug may need to take it with other medications.

Indication

Eltrombopag is mainly indicated for the treatment of patients having :
• Reduced platelet levels due to chronic immune thrombocytopenia
• Reduced platelet counts due to chronic hepatitis C virus infection
• Severe Aplastic Anemia :
• First line treatment of severe Aplastic Anemia
• Treatment of refractory severe Aplastic Anemia.

Mechanism Of Action

Eltrombopag be part of a class of drugs called thrombopoietin (TPO) receptor agonists. Classification of drugs is an association of medications which work in a similar way. These drugs are often used to treat similar conditions. Eltrombopag works by raise cells in bone marrow and leads these cells to make various platelets. This effect reduces the risk of bleeding.

Dosage and administration

Chronic Immune Thrombocytopenia:
Indicated only in patients with chronic immune thrombocytopenia whose clinical condition increases bleeding risk

First-line therapy:
Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA)

Usual dose: 
150 mg PO qDay for 6 months
Do not give more than starting dose; total duration is 6 months

Common Side Effects

• low red blood cells
• nausea
• fever
• weakness
• pain in head
• cough
• decreased appetite
• flu
• diarrhea

Precautions

The drug causes warning condition, call the doctor while new medication interaction
Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increase the risk of death.
If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.
If the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse.

Drug Interaction

Eltrombopag interaction with these drugs ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads an increase of side effects. hence the doctor may reduce the dosage of these drugs if required.
Eltrombopag co-administration with Cholesterol-reducing drugs like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin. Have high side effects can contain muscle pain. The doctor may reduce the dosage of your cholesterol drugs.

Lactation

The presence of Eltrombopag or metabolites in human milk, the drug has possible serious side effects for the breastfed child. The drug is not recommended during breastfeeding

Pregnancy

Pregnancy category is C
Use the Eltrombopag with caution if asset outweighs risks. Animal studies reveal risk and human studies not available or neither animal nor human studies done.

Storage

Store at room temperature 20°C to 25°C.
Discard the left-out medicine if not used within 30 minutes

Missed Dose

In case of a missed dose, patients must consult with a medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/eltrombopag.php

Cabozantinib tablet online | Apple Pharmaceuticals

Description

Cabozantinib is a prescription drug which is used under the supervision of doctors
Cabozantinib belongs to targeted therapy drug used to cure medullary thyroid cancer and kidney cancer that has spread and It is label includes a black box warning of gastrointestinal perforations, fistulas, and hemorrhage.

Indication

Cabozantinib is used for the treatment of
Metastatic medullary thyroid cancer
Advanced renal cell carcinoma (RCC) who have to get before anti-angiogenic therapy.

Mechanism Of Action

Cabozantinib is a group of targeted therapy drug known as a tyrosine kinase inhibitor. It works by prohibiting the signals inner cancer cells which made them develop and divide. This may help to restrict or reduce the development of cancer. It can also prevent new blood vessels growing in cancer. Cancer cells necessary to make new blood vessels, so they can grow and spread.

Dosage and administration

Do not prescribe substitution for Cabozantinib tablets with Cabozantinib capsules.
The usual dose of Cabozantinib is 60 mg.
Administration Cabozantinib is without food.
Inform the patients not to eat for at least 2 hours before and 1 hour after taking Cabozantinib. Follow the treatment until the patient no longer experiences clinical benefit or experiences unacceptable toxicity.

Side Effects

• Hemorrhage
• GI perforations and fistulas
• Thrombotic events
• Hypertension and hypertensive crisis
• Diarrhea
• Palmar-plantar erythrodysesthesia
• Reversible posterior leukoencephalopathy syndrome.

Precautions

Monitor the patients for symptoms of perforations and fistulas contain abscess. stop Cabozantinib in patients who experience a perforation or a fistula.
Do not administer Cabozantinib to patients with a present history of hemorrhage or hemoptysis.
Discontinue the Cabozantinib in patients who develop an acute myocardial infarction, cerebral infarction, or any other clinically significant arterial thromboembolic complication.
Discontinue the Cabozantinib for the patient if have severe hypertension that cannot be controlled with anti-hypertensive therapy.

Drug Interaction

While combination with strong CYP3A4 inhibitor will increase the single dose plasma Cabozantinib exposure by 38%.
While combination with strong CYP3A4 inducers will decrease the single dose plasma Cabozantinib exposure by 77%
Concomitant use with MRP2 inhibitors may increase the exposure to Cabozantinib

Contraindication

Cabozantinib is contraindicated patients having a hypersensitivity reaction to the active substance or its excipients.

Pregnancy

Based on studies of animal and mechanism of action, Cabozantinib will cause fetal harm when given to pregnant women.
Advice the female not to become pregnant while on treatment with Cabozantinib.

Lactation

During treatment with Cabozantinib, advise the women not to breastfeed to infants

Storage

Store the drug at 20°C to 25°C
Keep away from the children resistances

Missed Dose

If the patient vomits after taking a dose of Cabozantinib or missed to take a dose, they should not take an extra dose, but to take the next dose at the regular time, skip the missed dose. Do not take the missed dose within 12 hours of next dose.

FOR MORE INFORMATION:

EMAIL:

applepharmaceutical@gmail.com

PHONE:

91- 9987711567

VISIT US:

anti-cancer-drugs.com/cabozantinib.php